Loading...
Market
What will be the outcome of Soleno's DCCR FDA review by March 31, 2025?
3
Resolution / Starting Odds
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
FDA official announcements and press releases
Story
Soleno's Prader-Willi Drug Gets FDA Priority Review, No AdCom; Stock Up 12% to 52-Week High
Oct 8, 2024, 06:14 PM
Soleno Therapeutics announced a regulatory update for its DCCR (diazoxide choline) Extended-Release Tablets, aimed at treating Prader-Willi Syndrome. The FDA has decided not to convene an advisory committee (AdCom) for the drug, which is seen as a positive indicator for its potential approval. This decision has led to a significant increase in Soleno's stock price, with shares rising 12% to a new 52-week high, and 7.9% in pre-market trading. The drug has also received Priority Review status from the FDA, further boosting investor confidence. Analysts suggest that the lack of an AdCom reduces potential uncertainties and highlights the FDA's recognition of the unmet medical need for treating Prader-Willi Syndrome. Additionally, Soleno benefits from low cash burn, which could support further stock gains.
View original story
Similar markets
Approved • 25%
Approved with conditions • 25%
Rejected • 25%
Review extended • 25%
Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Request for More Data • 25%
Approval recommended • 25%
Approval not recommended • 25%
No consensus • 25%
Meeting postponed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved • 25%
Approved with Conditions • 25%
Not Approved • 25%
Decision Delayed • 25%
Top-selling PWS treatment • 25%
Moderate market success • 25%
Limited market impact • 25%
Withdrawn from market • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%